胶体^(32)P与p53基因治疗肺癌胸腔积液疗效的观察

Observation on the therapeutic effect of colloidal ^(32)P and p53 gene for the treatment of malignant pleural effusion induced by lung cancer

目的:探讨胶体32P与p53基因治疗肺癌胸腔积液的近期疗效和毒副作用。方法:65例确诊为肺癌并发单侧癌性胸腔积液的患者,随机分为3组。A组用重组人p53腺病毒注射液联合胶体32 P-磷酸铬(胶体32 P)治疗,B组单用胶体32P,C组单用重组人p53腺病毒注射液治疗。各入组者均每月治疗1次,治疗2次后评价疗效。结果:A组总有效率为81.8%,B组总有效率为52.4%,C组总有效率为40.9%,B组与C组之间比较,差异无统计学意义,χ2=0.57,P>0.05;B、C组分别与A组比较,差异均有统计学意义,χ2值分别为4.24和7.77,P值均<0.05;3组患者恶心、呕吐和粒细胞减少差异无统计学意义,A和C组均有5例发热,与B组无发热比较,差异有统计学意义,P值均为0.048。结论:单独使用胶体32P或p53基因治疗肺癌胸腔积液疗效有限;胶体32P与p53基因联合治疗可以有效地控制肺癌胸腔积液。

OBJECTIVE： To evaluate the curative effect and side effect of colloidal 32p and p53 gene for the treatment of malignant pleural effusion induced by lung cancer. METHODS： Totally 65 patients diagnosed as hmg cancer with single side malignant pleural effusion were randomly divided into 3 groups. The patients of group A were treated by recombinant adenovirus p53 injection （rAD-p53） combined with colloidal chromic phosphate 32p （colloidal 3z p）. The patients of group B were treated by colloidal 32p. The patients of group C were treated by recombinant rAIYp53 ,per month. The therapeutic effects were evaluated after 2 courses. RESULTS： The total effective rate（CR＋PR） was 81.8% in group A and 52.4% in group B and 40.9 % in group C. There was no significant difference between group B and C （X2= 0. 57, P〉 0.05）, but there was significant difference between A and 2 other groups（X2 were 4.24 and 7.77 respectively,P〈0.05）. CONCLU- SION： The effect of individual use of colloidal 32p or rAd-p53 for the treatment of malignant pleural effusion induced by lung cancer is limited, the combination of both can effectively control pleural effusion induced by lung cancer.